KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Net Margin (2016 - 2025)

Historic Net Margin for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to 13.01%.

  • TherapeuticsMD's Net Margin rose 206900.0% to 13.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.19%, marking a year-over-year decrease of 326000.0%. This contributed to the annual value of 7.44% for FY2024, which is 2055200.0% up from last year.
  • Latest data reveals that TherapeuticsMD reported Net Margin of 13.01% as of Q3 2025, which was up 206900.0% from 0.63% recorded in Q2 2025.
  • TherapeuticsMD's Net Margin's 5-year high stood at 36538.51% during Q2 2022, with a 5-year trough of 4481.44% in Q1 2022.
  • Over the past 5 years, TherapeuticsMD's median Net Margin value was 6.0% (recorded in 2024), while the average stood at 1329.46%.
  • Within the past 5 years, the most significant YoY rise in TherapeuticsMD's Net Margin was 367239400bps (2022), while the steepest drop was -42832000bps (2022).
  • TherapeuticsMD's Net Margin (Quarter) stood at 268.5% in 2021, then tumbled by -84bps to 42.66% in 2022, then soared by 207bps to 131.08% in 2023, then plummeted by -84bps to 20.69% in 2024, then plummeted by -37bps to 13.01% in 2025.
  • Its Net Margin was 13.01% in Q3 2025, compared to 0.63% in Q2 2025 and 4.33% in Q1 2025.